Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15


Target-Based Screening against eIF4A1 Reveals the Marine Natural Product Elatol as a Novel Inhibitor of Translation Initiation with In Vivo Antitumor Activity.

Peters TL, Tillotson J, Yeomans AM, Wilmore S, Lemm E, Jiménez-Romero C, Amador LA, Li L, Amin AD, Pongtornpipat P, Zerio CJ, Ambrose AJ, Paine-Murrieta G, Greninger P, Vega F, Benes CH, Packham G, Rodríguez AD, Chapman E, Schatz JH.

Clin Cancer Res. 2018 Sep 1;24(17):4256-4270. doi: 10.1158/1078-0432.CCR-17-3645. Epub 2018 May 29.


Discovery of Potent 17β-Hydroxywithanolides for Castration-Resistant Prostate Cancer by High-Throughput Screening of a Natural Products Library for Androgen-Induced Gene Expression Inhibitors.

Xu YM, Liu MX, Grunow N, Wijeratne EM, Paine-Murrieta G, Felder S, Kris RM, Gunatilaka AA.

J Med Chem. 2015 Sep 10;58(17):6984-93. doi: 10.1021/acs.jmedchem.5b00867. Epub 2015 Aug 31.


The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts.

Ihle NT, Paine-Murrieta G, Berggren MI, Baker A, Tate WR, Wipf P, Abraham RT, Kirkpatrick DL, Powis G.

Mol Cancer Ther. 2005 Sep;4(9):1349-57.


Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling.

Ihle NT, Williams R, Chow S, Chew W, Berggren MI, Paine-Murrieta G, Minion DJ, Halter RJ, Wipf P, Abraham R, Kirkpatrick L, Powis G.

Mol Cancer Ther. 2004 Jul;3(7):763-72.


Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha.

Welsh S, Williams R, Kirkpatrick L, Paine-Murrieta G, Powis G.

Mol Cancer Ther. 2004 Mar;3(3):233-44.


Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors.

Beliakoff J, Bagatell R, Paine-Murrieta G, Taylor CW, Lykkesfeldt AE, Whitesell L.

Clin Cancer Res. 2003 Oct 15;9(13):4961-71.


Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer.

Bagatell R, Khan O, Paine-Murrieta G, Taylor CW, Akinaga S, Whitesell L.

Clin Cancer Res. 2001 Jul;7(7):2076-84.


Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents.

Bagatell R, Paine-Murrieta GD, Taylor CW, Pulcini EJ, Akinaga S, Benjamin IJ, Whitesell L.

Clin Cancer Res. 2000 Aug;6(8):3312-8.


Wortmannin inhibits the growth of mammary tumors despite the existence of a novel wortmannin-insensitive phosphatidylinositol-3-kinase.

Lemke LE, Paine-Murrieta GD, Taylor CW, Powis G.

Cancer Chemother Pharmacol. 1999;44(6):491-7.


Enhancement of chemotherapy by manipulation of tumour pH.

Raghunand N, He X, van Sluis R, Mahoney B, Baggett B, Taylor CW, Paine-Murrieta G, Roe D, Bhujwalla ZM, Gillies RJ.

Br J Cancer. 1999 Jun;80(7):1005-11.


Diaryl chalcogenides as selective inhibitors of thioredoxin reductase and potential antitumor agents.

Engman L, Cotgreave I, Angulo M, Taylor CW, Paine-Murrieta GD, Powis G.

Anticancer Res. 1997 Nov-Dec;17(6D):4599-605.


Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained.

Taylor CW, Wang LM, List AF, Fernandes D, Paine-Murrieta GD, Johnson CS, Capizzi RL.

Eur J Cancer. 1997 Sep;33(10):1693-8.


Human tumor models in the severe combined immune deficient (scid) mouse.

Paine-Murrieta GD, Taylor CW, Curtis RA, Lopez MH, Dorr RT, Johnson CS, Funk CY, Thompson F, Hersh EM.

Cancer Chemother Pharmacol. 1997;40(3):209-14.


Transfection with human thioredoxin increases cell proliferation and a dominant-negative mutant thioredoxin reverses the transformed phenotype of human breast cancer cells.

Gallegos A, Gasdaska JR, Taylor CW, Paine-Murrieta GD, Goodman D, Gasdaska PY, Berggren M, Briehl MM, Powis G.

Cancer Res. 1996 Dec 15;56(24):5765-70.

Supplemental Content

Loading ...
Support Center